A Year Since Pfizer’s Big Breakthrough, Are Vaccine Stocks Still Worth Investing In?

A Year Since Pfizer’s Big Breakthrough, Are Vaccine Stocks Still Worth Investing In?

It’s been almost a year since Pfizer published incredibly strong efficacy data from its phase 3 Covid-19 vaccine trials, setting the stage for one of the largest inoculation drives in history. Our theme of Covid-19 Vaccine Stocks has outperformed meaningfully since then, rising by about 115%…